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AbstrACt
Introduction Type 2 diabetes is common, affecting 
over 400 million people worldwide. Risk of serious 
complications can be reduced through use of effective 
treatments and active self- management. However, 
people are often concerned about starting new medicines 
and face difficulties in taking them regularly. Use of 
brief messages to provide education and support self- 
management, delivered through mobile phone- based text 
messages, can be an effective tool for some long- term 
conditions. We have developed messages aiming to 
support patients’ self- management of type 2 diabetes 
in the use of medications and other aspects of self- 
management, underpinned by theory and evidence. 
The aim of this trial is to determine the feasibility of a 
large- scale clinical trial to test the effectiveness and cost- 
effectiveness of the intervention, compared with usual 
care.
Methods and analysis The feasibility trial will be a 
multicentre individually randomised, controlled trial in 
primary care recruiting adults (≥35 years) with type 2 
diabetes in England. Consenting participants will be 
randomised to receive short text messages three times 
a week with messages designed to produce change in 
medication adherence or non- health- related messages 
for 6 months. The aims are to test recruitment methods, 
retention to the study, the feasibility of data collection 
and the mobile phone and web- based processes of a 
proposed definitive trial and to refine the text messaging 
intervention. The primary outcome is the rate of recruitment 
to randomisation of participants to the trial. Data, including 
patient reported measures, will be collected online at 
baseline and the end of the 6- month follow- up period. With 
200 participants (100 in each group), this trial is powered 
to estimate 80% follow- up within 95% CIs of 73.8% to 
85.3%. The analysis will follow a prespecified plan.
Ethics and dissemination Ethics approval was 
obtained from the West of Scotland Research Ethics 
Committee 05. The results will be disseminated through 
conference presentations, peer- reviewed journals and 
will be published on the trial website: www. summit- d. 
strengths and limitations of this study
 ► The use of brief messages to support self- 
management and provide motivation and education, 
delivered through mobile phone- based text mes-
sages, can be an effective tool for some long- term 
conditions.
 ► There are a few trials testing the impact of brief 
messaging in type 2 diabetes; although some have 
systematically developed messages mapped to the-
oretical constructs, many are at risk of bias and may 
be limited in their application to specific contexts.
 ► The objective of the SuMMiT- D Feasibility trial is to 
test recruitment and randomisation of participants 
and collection of proposed primary and secondary 
outcome data in planning for a large, outcomes 
based, randomised controlled trial.
 ► The messages evaluated in this study are: (1) tar-
geted at constructs identified as being related to 
medication adherence by systematic reviews of 
the literature and (2) demonstrated to have fidelity 
to intended behaviour change techniques (as rated 
by experts) and acceptability to target population (as 
rated by patients).
 ► Potential mechanisms for the action of the brief 
messages will be assessed through changes in 
constructs that are related to medication- taking be-
haviour, questions based on the technology accep-
tance model and self- report medication adherence.
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org (SuMMiT- D (SUpport through Mobile Messaging and digital health 
Technology for Diabetes)).
trial registration number ISRCTN13404264.
IntroduCtIon
Type 2 diabetes is one of the most common long- term 
conditions affecting 422 million people worldwide1 
and 4.7 million people in the UK.2 It can lead to major 
complications including cardiovascular disease, renal 
failure and neuropathy.3 The global burden of diabetes 
is projected to reach up to 2.2% of global gross domestic 
product,4 and many of these costs are due to prevent-
able complications. Prevention includes the use of 
treatments of proven efficacy5 6 alongside supporting 
self- management.7 However, concerns about medicines 
and difficulties in taking them regularly, whether inten-
tional or unintentional, are common8 and lead to poor 
diabetes control and increased use of health resources.9 
The cost of non- adherence to diabetes medication in the 
UK has been estimated at £100 million per year in avoid-
able treatment costs.10 A wide range of services are avail-
able to support people in better use of their medicines, 
but evidence of their effectiveness and cost- effectiveness 
is weak.11 These services are often targeted at particular 
groups of individuals and are frequently designed as ‘one- 
off’ interventions. Examples include medication reviews, 
education and addressing cost issues.12 Understanding 
and improving this situation could make a major contri-
bution to health and healthcare costs.
Systematic reviews do not provide strong evidence to 
support the wider use of current approaches to devel-
oping interventions to improve adherence.13 Brief 
messages delivered at a wide scale and low cost via digital 
health systems added to usual care have been shown to be 
effective in improving health for some conditions and are 
a promising approach to the problem.14
Systematic reviews of text messages to support patients 
to adhere to treatment, and of mobile health interven-
tions in diabetes, identify some effective interventions. 
There are a few trials testing the impact of brief messaging 
in type 2 diabetes; although some have systematically 
developed messages mapped to theoretical constructs, 
many are at risk of bias and may be limited in their 
application to specific contexts.14 15 Recent trials of text 
messaging for cardiovascular risk prevention and blood 
pressure lowering have shown clinically relevant changes 
in outcomes compared with usual care.16 17
In addition, there is substantial evidence that tailored 
interventions are more effective than generic interven-
tions.18 Tailored interventions may be seen by recipients 
as more personally relevant, so they will be more likely to 
attend to, read, understand and act on them. In addition, 
tailored interventions are designed to change determi-
nants of the target behaviour that are relevant to partic-
ular individuals or to small subgroups of individuals; they 
therefore more precisely target the determinants of the 
individual’s behaviour.
SUpport through Mobile Messaging and digital health 
Technology for Diabetes (SuMMiT- D) is a programme of 
work composed of three phases: formative work, a feasi-
bility trial and a large scale, effectiveness randomised 
controlled trial of a mobile phone- based system intended 
to deliver brief, tailored, behaviour change messages to 
people with type 2 diabetes focusing on use of medica-
tion. The intervention is intended to focus on a broad 
range of individuals with type 2 diabetes, but those with 
younger onset diabetes and using insulin alone were 
not included, as these features can require care using 
different pathways. In the formative work for this trial, 
we identified theoretical constructs and features of inter-
vention content found to be associated with medication 
adherence in patients with type 2 diabetes and mapped 
these onto a standard taxonomy for behaviour change 
techniques (BCTs), that is, active ingredients of interven-
tions used to promote behavioural change.19 20 We then 
developed a large set of messages to target each BCT and 
examined which types of messages are most useful and 
easy to understand for people starting and taking an oral 
diabetes medicine and the extent to which it might be 
helpful for patients to decide on the types of messages 
they want to receive. We received input from approxi-
mately 300 patients with type 2 diabetes and healthcare 
professionals caring for this patient population. Prelimi-
nary findings of this trial development work were used to 
develop this feasibility trial with scope for further refine-
ment of the system for the main clinical trial.
The primary objective of the SuMMiT- D Feasibility trial 
is to test recruitment and randomisation of participants 
to the trial. We will test collection of planned primary 
and secondary outcome data in planning for a large, 
outcomes- based, randomised controlled trial. We will 
assess the feasibility and acceptability of the intervention 
for patients and healthcare professionals; the willingness 
of participants to be randomised; follow- up rates; resource 
use; and trial procedures. We will also carry out a process 
evaluation of how the system is used and refine the way it 
is embedded within usual care. Potential mechanisms for 
the action of the brief messages will be assessed through 
changes in hypothesised health psychology constructs 
relating to use of medication, self- report medication 
adherence,21 and questions based on the technology 
acceptance model.22
MEthods And AnAlysIs
The SuMMiT- D Feasibility trial protocol is reported 
according to Standard Protocol Items: Recommenda-
tions for Interventional Trials (SPIRIT) and Medication 
Adherence Reporting Guidelines (EMERGE) recommen-
dations.23 24
Patient and public involvement (PPI)
Patient members of the public are integral to this trial. A 
panel of 11 PPI members with type 2 diabetes was set up 
and continues to inform our work, reviewing all patient 
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Figure 1 Trial profile.
documentation and research findings, and supports the 
development of the intervention.
All patient facing documents for the SuMMiT- D Feasi-
bility trial, including the participant information sheet, 
informed consent form, posters, user guides and website, 
were reviewed by PPI panel members. The panel has been 
kept up to date with frequent trial updates in the form of 
an email newsletter, also published on the trial website ( 
www. summit- d. org). The results of the study will be made 
available to trial participants, PPI panel members and 
participating genenral practices practices on the trial 
website.
trial design
SuMMiT- D Feasibility is a primary care- based, two- arm, 
individually randomised controlled, parallel group trial 
aiming to recruit a total of 200 patients across 20 general 
practice sites in England. Patients with type 2 diabetes will 
be randomly allocated to receive an individually tailored 
short messaging system (SMS) text messaging- based inter-
vention for 26 weeks that aims to encourage and support 
them in developing a habit of taking their medication 
as intended (ie, to promote effective implementation of 
dosing and treatment continuation)25 and provides hints 
and tips to help them with other aspects of living with 
the condition alongside usual care (treatment arm) or 
to usual care with the addition of infrequent non- health- 
related messages (control arm) (figure 1).
Intervention
Intervention arm: condition-specific tailored text messaging 
system and usual care
Participants assigned to the intervention group will receive 
brief health- related SMS text messages, based on system-
atic review of the evidence identifying determinants of 
medication- taking behaviour.20 Messages were developed 
based on systematic review evidence by experts20 and 
were refined in an iterative process of ensuring accept-
ability based on patient feedback and demonstration 
of fidelity to intended behaviour change determinants, 
as rated by an independent group of experts.26 A more 
detailed description of the intervention is given in the 
accompanying template for intervention description and 
replication (TIDieR) checklist. Examples of messages are 
given in the supplementary file (see online supplemen-
tary appendix 1).
The intervention is a digital health system with the 
following components:
i. Participants will be sent up to four automated text 
messages per week with an average frequency of 
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three per week relating to diabetes management and 
use of medicine.
ii. The library of text messages uses different BCTs to 
target health- related behaviour change relating to 
use of medicines, as well as messages targeting other 
aspects of diabetes care (including diet and exercise).
iii. The types of messages sent will be tailored to partici-
pants based on time since starting new glucose, blood 
pressure and cholesterol- lowering medication and 
current smoking status.
iv. Frequency of messages received using a particular 
group of BCTs can be modified based on a partici-
pant’s response to individual messages received 
through sending a text message in response to a 
particular message. Participants may incur a cost for 
sending messages in response depending on their 
network plan.
v. The style of messages will be patient centred and will 
encourage patients to seek further relevant informa-
tion (including the use of links where possible to se-
lected external websites, eg, Diabetes UK).
Control arm: usual care and one non-health-related message a 
month
Participants assigned to usual care will receive non- health- 
related text messages at a frequency of approximately one 
every 4 weeks. Care will otherwise not differ from usual 
care.
outcomes
The primary outcome is the rate of recruitment to rando-
misation of participants to the trial. Details of outcomes 
and measurement are shown in table 1. We will measure 
recruitment against planned recruitment rates for the 
proposed main trial and number of people showing an 
interest in the trial and not proceeding or those who with-
draw from the control group and give a reason.
Secondary outcomes (table 1) focus on feasibility of 
collection of clinical and economic measurement data 
for the proposed main trial. They include the availability 
of HbA1c, systolic blood pressure and total to HDL 
cholesterol ratio data from medical records, retention 
rates and proportion of prescribing data available. A self- 
report questionnaire will assess: medication adherence,21 
health status with the EuroQol 5- Dimension, 5- Level 
(EQ- 5D- 5L),27 resource use for the health economic anal-
ysis, technology acceptance22 and constructs targeted by 
SMS and hypothesised to mediate the effects of the inter-
vention on adherence.28
Procedures and assessments
Participants who express interest in taking part in the trial 
will be screened by the trial team and will consent and 
submit their baseline questionnaires either online or on 
paper according to their preference. Participants will be 
randomised by the trial team and will receive messages 
for 26 weeks from randomisation to final follow- up. All 
participants will be asked to complete the same set of 
questionnaires at baseline and at the end of their 26- week 
follow- up period. Medical notes reviews will be conducted 
at baseline, 6 months and 18 months from randomisation.
Recruitment
Potential participants will be identified through general 
practices in England. Participating practices fall under 
four Clinical Research Networks: Thames Valley & South 
Midlands, Greater Manchester, West Midlands and South 
West Peninsula.
Healthcare professionals will screen their type 2 diabetes 
clinic lists and will invite eligible patients. Patients will 
receive an invitation letter and summary information 
leaflet. Eligible patients may also be contacted by phone, 
email or text by the practice team up to three times.
Expressions of interest
People interested in taking part can send their full name 
by SMS text message to the trial team to register their 
interest. If potential participants have any difficulties in 
registering their interest in the trial, they will also be able 
to contact the team via phone or email and will receive 
support in registering as required.
Screening assessment
Following an expression of interest, further information 
about the study will be provided by email or by post as 
requested. Eligibility will be confirmed by phone.
Inclusion criteria
Eligible participants are ≥35 years of age, taking oral 
glucose lowering treatment, blood pressure- lowering 
treatment or lipid- lowering treatment either alone or in 
combination. They have access to a mobile phone and are 
able, if necessary, with help (eg, relative, friend, neigh-
bour), to send, understand and retrieve brief SMS text 
messages in the English language. Participants who are 
using insulin treatment without also concomitant use of 
oral glucose- lowering treatment; who are pregnant, within 
3 months postpartum or planning pregnancy during the 
course of the trial; have a serious medical condition that, 
in the opinion of the investigator, makes them ineligible; 
have been admitted to hospital within the last 3 months 
for hyperglycaemia or hypoglycaemia, are ineligible.
Informed consent
Participants will provide consent either online or on 
paper.
Baseline and follow-up assessments
The following questionnaires will be administered (online 
or by post) at the baseline assessment: the Medication 
Adherence Report Scale (MARS) Self- Report Scale,21 the 
EQ- 5D- 5L Scale,27 a set of measures developed for the 
study based on the technology acceptance model22 and a 
healthcare utilisation record to allow healthcare resource 
use to be costed. A further set of measures assess the 
constructs that will be targeted by the BCTs within the 
messages. These constructs are hypothesised to mediate 
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Table 1 Schedule of trial outcomes and measures
Outcome Measure
Timing (months)
0 6 18
Participant recruitment to the trial. Recruitment against planned recruitment rates. ×
Participant willingness to be randomised. Number of people showing an interest and not 
proceeding or those who withdraw from the control 
group and give a reason.
×
Feasibility of collection of clinical measurement data 
for the proposed clinical trial.
Retrieval of measurements of HbA1c, systolic blood 
pressure and cholesterol for trial participants from 
medical record.
× ×
Willingness of participants to be followed up over the 
26- week period postrandomisation.
Retention and follow- up rates. ×
Feasibility of collection of prescribing data on trial 
participants.
Proportion of medication possession ratio for 
glucose, blood pressure and lipid- lowering 
medication obtainable from prescribing data in 
participant’s medical record.
×
Feasibility of collecting self- reported questionnaire 
measures.
Proportion of completed self- reported measures 
(Demographics and Additional Information 
Questionnaire; MARS Self- Report Scale; EQ- 5D- 5L 
Health Status Questionnaire; Healthcare Utilisation 
Record Questionnaire (cost measurement); and 
Health Psychology and Technology Acceptance 
Questionnaire.
× ×
Feasibility of collecting medical history and baseline 
medication from medical record.
Proportion of data obtained. ×
Feasibility and acceptability of the intervention for 
patients and healthcare professionals (including 
general practitioners, nurses, receptionists and 
pharmacists). Qualitative process evaluation.
Data obtained through focus groups, qualitative 
interviews with patients and healthcare staff.
× ×
Assess reliability of measures of hypothesised 
mechanism of action and sensitivity to change in 
response to receipt of SMS messages. Examine 
relationship between these measures and self- 
reported adherence, as preliminary process analysis. 
(Quantitative process evaluation).
Change in quantitative mechanism of action 
measures and relationship between changes in these 
measures and self- reported adherence.
× ×
Changes in clinical measurement data. HbA1c, systolic blood pressure and cholesterol for 
trial participants from medical record.
× × ×
Information on message delivery and interaction with 
participants.
Automated reports from messaging service on 
messages delivered and interactive messaging.
× ×
EQ- 5D- 5L, EuroQol 5- Dimension, 5- Level; HbA1c, glycated haemoglobin; MARS, Medication Adherence Report Scale.
the effects of the intervention on medication taking 
behaviour, in line with the logic model we have developed 
based on the Health Action Process Approach (figure 2, 
table 1 and online supplementary appendix 2).28
All self- report data will be collected either online or 
on paper according to the participant’s preference. The 
same measures are collected at 26 weeks after randomisa-
tion alongside clinical record data.
randomisation
Participants will be randomised after consent and when 
all baseline assessments have been completed. Partici-
pants will be allocated in a 1:1 ratio to either the inter-
vention or the control arm. Randomisation will be 
done using a validated secure web- based randomisation 
programme (Sortition) provided by the University of 
Oxford Primary Care Clinical Trials Unit (PC- CTU). 
Allocation will be carried out with a non- deterministic 
minimisation algorithm to ensure groups are balanced 
for important baseline prognostic and other factors: 
study site, age (<65/≥65 years), gender (male/female), 
duration of diabetes (<5 years/≥5 years) and number of 
medications (<5/≥5). The allocated intervention will 
be implemented directly by the platform on which the 
digital health system is run. Apart from the qualitative 
research team and the engineering team, allocation is 
blinded to all other trial and healthcare staff. Due to the 
nature of the study, unblinding is not required during 
the trial.
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Figure 2 Logic model showing anticipated mechanisms of action in the SuMMIT- D Feasibility study, based on the Health 
Action Process Approach. (a) This construct includes both beliefs about the necessity of taking medication, and concerns about 
taking that medication.
discontinuation of intervention or withdrawal from trial
Participants can withdraw from the trial at any time. 
Participants can also choose to pause or stop receipt of 
text messages by sending a text message or contacting 
the trial office by telephone or post. Adverse events are 
collected, and serious unexpected adverse events related 
to the intervention are determined by the chief investi-
gator and reported in line with local procedures.
statistical analysis
Power
With 200 participants (100 in each group), the feasibility 
trial is powered to estimate 80% follow- up within 95% CIs 
of 73.8% to 85.3%.
Analysis
The primary outcome will be the number of patients 
recruited to randomisation as a proportion (with 95% CI) 
of the target recruitment number. Secondary outcomes 
will be reported overall and separately by allocated arm.
An intention- to- treat approach will be used for an explor-
atory analysis of secondary outcomes by allocated arm. 
Continuous outcomes will be analysed using an analysis 
of covariance adjusting for minimisation factors. Results 
will be presented as an adjusted difference in means with 
95% CI. Binary outcomes will be analysed in a similar 
way using log binomial regression models (adjusting for 
minimisation factors). Results will be presented as relative 
risks with 95% CIs. There will be no formal assessment of 
treatment efficacy for this feasibility study.
Analysis of utility and costs
Data collected on healthcare utilisation will be assessed 
for completeness. The items recorded include patient 
contacts with healthcare professionals, use of primary 
care services, hospital outpatient appointments, 
accident and emergency visits, and inpatient stays, 
prescribed and purchased medications, and personal 
social services. The proportion of complete and 
returned questionnaires will be reported. Total costs 
associated with each item of resource will be estimated 
based on unit costs from standard sources29 30 and 
presented descriptively.
The costing is conducted from the perspective of the 
National Health Service (NHS), and therefore the cost to 
the patient is not considered; we will, however, estimate 
costs of responding to text messages using estimates from 
average network tariffs and data collected on the quantity 
of digital information transmitted.
Responses to the EQ- 5D- 5L questionnaire will also be 
examined for completeness and reported by propor-
tion of returned questionnaires and items with a valid 
response. Health utility values corresponding to patients’ 
EQ- 5D- 5L profiles will be calculated by mapping the 
5 L descriptive system data onto the 3 L value set31 and 
presented descriptively.
Process evaluation
We will perform a mixed- methods process analysis, 
consisting of a qualitative element and a quantitative 
element. The qualitative process evaluation will examine 
the experience of participants and health professionals 
in their use of and implementation of the messaging 
system. Longitudinal interviews with up to 30 participants 
will take prior to use of the system and after the 26- week 
follow- up. Additionally, up to 30 healthcare professionals 
will be invited to share their experiences of taking part in 
this trial.
Interviews with trial participants
Participants who consent to taking part in the embedded 
qualitative study will be purposefully selected by charac-
teristics including age, gender, length of time of diabetes 
and type of medication and invited to share their views 
on engagement with and content of the messaging system 
and to provide insight into how it was implemented in 
daily life, identify issues around potential attrition and 
inform final procedures for the main trial.
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Interviews and/or focus groups with healthcare professionals
Healthcare staff from practices taking part in the trial will 
be invited to take part in focus groups or qualitative inter-
views to share their experience of recruiting for this trial 
and how the intervention was implemented in routine 
clinical care. Eligible staff will be those with a potential 
role in the implementation of a text message system 
or who have contact with patients with type 2 diabetes. 
These will include GPs, practice nurses, receptionists and 
healthcare assistants.
Analysis of qualitative data: trial participants
Thematic analysis will be used inductively to identify key 
issues, focussing on similarities and differences identified 
in themes to understand the issues that are important to 
the participants.32 We will use NVivo and mind- mapping 
software to code data, identify themes and interpret 
these and their relationship. The data analysis will be 
inductive.
Analysis of qualitative data: healthcare professionals
We will follow a semistructured topic guide based on 
the core constructs of extended normalisation process 
theory (NPT)33: coherence, reflexive monitoring, cogni-
tive participation and collective action to ensure key areas 
are covered while allowing flexibility to follow up topics 
introduced by participants. NVivo software will be used to 
facilitate data organisation, analysis and the development 
of themes. The analysis will use a thematic approach 
informed by NPT.32
Quantitative process analysis
To facilitate understanding of mechanism of the interven-
tion, the effect of the intervention on the set of measures 
based on the logic model (figure 2 and table 1) will be 
analysed using a per- protocol analysis for responders, 
according to allocated group. This will identify if these 
measures have been affected by the intervention. A 
further analysis will examine how these measures in the 
logic model (controlling for baseline) predict change 
in self- reported medication adherence using hierar-
chical multiple regression techniques.34 This analysis will 
thereby assess extent of association between measures 
in the logic model and self- reported medication adher-
ence.35 These analyses will be used in conjunction with 
the qualitative analyses described above to inform deci-
sions about selection of SMS messages relating to partic-
ular BCTs and potentially refinement of the logic model 
and selection of measures for the full trial. Receipt of 
messages on participants’ mobile phones will be moni-
tored throughout the trial.
data management
All trial data will be entered on electronic case report 
forms. The clinical database is built on Research Elec-
tronic Data Capture, a secure, web- based application 
designed to support data capture for research studies.36
Ethics and dissemination
The trial will be conducted according to the principles 
of the Declaration of Helsinki and in accordance with 
other relevant national guidelines, regulations, acts and 
using Good Clinical Practice guidelines. The University 
of Oxford sponsors the trial.
The role of the Trial Steering Committee is taken on 
by the National Institute for Health Research Programme 
Steering Committee.
dissemination plan
The results of this trial will be submitted to a peer- reviewed 
journal for publication.
Recruitment to the SuMMiT- D Feasibility study began 
with the first participant randomised on 26 November 
2018 and the last participant randomised on 16 April 
2019. Reporting of the trial is anticipated in the first 
quarter of 2020.
dIsCussIon
SuMMiT- D Feasibility will inform the design of a future 
large- scale randomised controlled trial, aiming to esti-
mate the clinical and cost- effectiveness of the text 
messaging intervention and identify difficulties that 
might be encountered in practice. If effective and imple-
mented in the NHS, this intervention could help reduce 
the burden of complications and increased costs associ-
ated with non- adherence. This research could also offer 
a model for technology- based self- management support 
that could be extended to other aspects of diabetes care 
and other long- term conditions.
The SuMMiT- D Collaborative Study Group are listed in 
online supplementary appendix 3 with their roles.
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